SEC Comment Letter for SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Jun 1, 2018
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: June 1, 2018 · CIK: 0001390478 · Accession: 0000000000-18-016884
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225140
Letter
May 31, 2018 Angelos M. Stergiou President and Chief Executive Officer SELLAS Life Sciences Group, Inc. 315 Madison Avenue, 4th Floor New York, NY 10017 Re:SELLAS Life Sciences Group, Inc. Registration Statement on Form S-1 Filed May 23, 2018 File No. 333-225140 Dear Dr. Stergiou: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Marianne C. Sarrazin, Esq. - Cooley LLP
Show Raw Text
May 31, 2018
Angelos M. Stergiou
President and Chief Executive Officer
SELLAS Life Sciences Group, Inc.
315 Madison Avenue, 4th Floor
New York, NY 10017
Re:SELLAS Life Sciences Group, Inc.
Registration Statement on Form S-1
Filed May 23, 2018
File No. 333-225140
Dear Dr. Stergiou:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Marianne C. Sarrazin, Esq. - Cooley LLP